Yasumatsu R, Matsuo M, Wakasaki T, Masuda M, et al. Clinical outcome in recurrent and/or metastatic head and neck cancer patients after discontinuation of nivolumab monotherapy due to immune-related adverse events. Acta Otolaryngol 2020 Aug 18:1-6. doi: 10.1080/00016489.2020.1807601.
PMID: 32808841